Luminex to Launch New Multiplex Instruments,Seek FDA OK for Warfarin PGx Assay Next Year | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Luminex plans to launch a next-generation multiplex instrument next year that will be able to process more analytes and produce results twice as fast as its current Luminex 200 instrument, company officials said during the firm’s annual investors meeting in New York last week.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.